Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | PDE9A | O76083 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512423 | 1.00 | TYK2 (0.45) | TYK2ALDH1A1HPGDHTTPDE5A | |
| SCHEMBL4511039 | 0.82 | TYK2 (0.44) | TYK2ALDH1A1HPGDHTTPDE5A | |
| SCHEMBL4520697 | 0.82 | TYK2 (0.44) | TYK2ALDH1A1HPGDHTTPDE5A | |
| SCHEMBL4524015 | 0.79 | TYK2 (0.50) | TYK2ALDH1A1HPGDHTTPDE5A | |
| SCHEMBL4511767 | 0.77 | ALDH1A1 (0.51) | TYK2ALDH1A1HPGDHTTPDE5A | |
| SCHEMBL4498996 | 0.76 | TYK2 (0.53) | TYK2ALDH1A1HPGDHTTPDE5A | |
| SCHEMBL4510202 | 0.76 | TYK2 (0.58) | TYK2ALDH1A1HPGDHTTPDE5A | |
| SCHEMBL4500032 | 0.76 | TYK2 (0.44) | TYK2ALDH1A1HPGDHTTPDE5A | |
| SCHEMBL4510912 | 0.75 | TYK2 (0.53) | TYK2ALDH1A1HPGDHTTPDE5A | |
| SCHEMBL4510948 | 0.73 | TYK2 (0.53) | TYK2ALDH1A1HPGDHTTPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | TYK2 3816/4885ALDH1A1 240/4885HPGD 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.